Aim: Slow coronary flow (SCF) is defined as a microvascular disorder characterized by slow advance of the contrast material administered during angiography, despite absence of epicardial coronary artery occlusion and delayed opacification of distal vascular structures. Genetically inherited ABO blood types are presumed to play role in coronary artery disease. In this study, the relationship between SCF and ABO blood types was investigated.
INTRODUCTION
SCF is a clinical condition categorized by slow advance of the administered contrast material within epicardial arteries without any angiographic sign of arterial occlusion (1). SCF has been shown to cause chest pain during exercise or at rest and the pathophysiology of SCF is still not clear. Currently, endothelial dysfunction, microvascular and vasomotor dysfunction, and increased thrombotic and inflammatory activities are believed to be possible contributors to this condition (2) (3) (4) . Several studies have documented the presence of myocardial ischemia with non-invasive tests in patients with SCF (5, 6) .
ABO blood type antigens are made of glycoproteins that are abundant on platelets, vascular endothelial cells, and erythrocytes (7) . Multiple reports have demonstrated an association between ABO blood types and cardiovascular disease (8) (9) (10) . It is well known that genetics can cause coronary artery disease. Since ABO blood types are genetically inherited, they may be involved in cardiovascular disease development.
In this retrospective case control study, the effect of ABO blood types on SCF was examined
METHODS

Study Design and Study population
A total of 250 subjects that underwent coronary angiography in our clinic between 2016 January and 2018 December were enrolled in the study. Angiographic images were evaluated retrospectively. One hundred and twenty five patients, who had SCF during angiography, were included in the study. One hundred and twenty five subjects, who had normal coronary arteries were designated the control group. Clinical and laboratory information including age, sex, diabetes mellitus (DM), blood pressure, smoking status, height, body weight, ABO blood type, and lipid profile were retrieved from the medical records. Echocardiography findings were obtained from medical records. Left ventricular ejection fraction measured by simpson method.
The study exclusion criteria were presence of lung or liver disease, chronic kidney disease, heart disease, infection, and hematological disease or systemic rheumatoid disease.This study was accepted by the ethics committeeand carried out with the guidelines put forth by the Declaration of Helsinki.
Laboratory parameters
A peripheral venous blood sample was collected from the antecubital vein before coronary angiography at our center. ABO blood typing was performed using a hemagglutination technique (Biotest, Germany) according to the manufacture's protocol. HDL-C, TG, LDL-C, and TC levels were analyzed using an Abbott Architect C16000 analyzer (Abbott Laboratory).
TIMI Frame Count for Diagnosis of SCF
Coronary angiography was achieved using the femoral approach and the angiograms were examined for SCF. Assessment of SCF was doneby two independent blind observers and TIMI frame count used for for diagnosis of SCF (11) . The mean values for coronary arteries visualization frames were, 22.2 ± 4.1 for LCx,36.2 ± 2.6 for LAD and 20.4 ± 3 for RCA.
Statistical analysis:
The SPSS, v 22.0, statistical progam (Chicago, USA) was used.Numerical and Categoricalvariables were given as mean±SD and percentage, respectively.For numerical variables, statistical analyses were made with independent samples using t-test/Mann-Whitney U-test. For categorical variables,chi-square test or Fisher's exact testwas used. A p-value <0.05 was considered statistically significant.
RESULTS
Baseline demographic,laboratory and echocardiographic findings of groups are shown in Table 1 . Age, gender, BMI, smoking status, DM, systolic/diastolic blood pressures were similar in both groups (p>0.05 for all).High density lipoprotein cholesterol(HDL-C) was higher in control group than SCF group (p=0.003). Low density lipoprotein cholesterol (LDL-C),triglyceride (TG) and totalcholesterol (TC) were elevated in SCF group as compared to the controls (p=0.003, p<0.001, p<0.001, and p<0.001, respectively). 
DISCUSSION
The association between SCF and ABO blood types were investigated in the present study. An association was found between blood type A and SCF. Recently, several studies examined the relationship between ABO blood types and coronary artery disease, and showed that non-A blood groups were associated with CAD (12, 13) . The present study is the first study to examine the association between SCF and ABO blood types.
SCF is responsible for nearly 7.0% of all cases undergoing coronary angiography due chest pain and suspicion of CAD (14) . Cardiac functions are compromised in the case of SCF.
Patients with SCF have been shown to have abnormalities of ventricular diastolic function, subclinical atherosclerosis, ventricular conductance disturbances, cardiac autonomic dysfunction, and increased ventricular arrhythmia (15) (16) (17) (18) . Patients with SCF have increased cardiac mortality and morbidity (19) . Several studies have shown an important role of increased inflammatory activity in pathophysiology of cardiovascular disease and arrhythmia (20) .
Increased inflammatory activity has also been documented in patients with SCF. The pathogenic mechanism regarding the association between blood type A and SCF may involve various causes. The ATP Binding Cassette 2 (ABCA2) gene and the ABO gene are both located on chromosome 9q34. In parallel with this information, this study showed significantly increased levels of LDL, TG, and TC among patients with SCF, whom have significantly higher frequency of blood type A compared to the control group. The high cholesterol levels might play role in development of microvascular disease, which is responsible for pathogenesis of SCF. Blood type antigen A is expressed not only on the red blood cells but also on other cells such as platelets and vascular endothelial cells [7] . In addition, non-O blood types have high plasma levels of von Willebrand factor, which increase the risk of vascular thrombosis. As conclusion, increased thrombotic activity and microvascular disease in the case of blood types A might be responsible for development of SCF. Some genetic studies have defined ABO gene as an important site for LDL cholesterol metabolism and the inflammatory biomarkers ICAM-1, E-selectin, and P-selectin. These molecules play active roles in hemostasis and inflammation.
Blood type antigen A may modulate the risk of SCF by influencing the levels of hemostasis and inflammatory proteins in circulation.
Major limitations of the present study are its single-centered design and the few numbers of patients. Another limitation is that inflammatory markers and hemostasis markers were not measured In conclusion, this study findings suggest that blood type A may pose an increased risk for SCF. However to investigate the association between ABO blood types and SCF, largescale, multi-centered studies that correlate ABO genotypes with hemostatic and inflammatory markers are required.
